STOCKWATCH
·
Pharmaceuticals
Quarterly Result13 Feb 2026, 05:30 pm

Sanjivani Paranteral Ltd. Reports 261.67 Lacs Net Profit for Quarter Ended 31st December 2025

AI Summary

Sanjivani Paranteral Ltd. has reported an unaudited net profit of 261.67 Lacs for the quarter ended 31st December 2025, an increase from the previous quarter's profit of 163.85 Lacs. The company's revenue from operations stands at 2086.32 Lacs for the quarter. Despite the increase in net profit, the Earnings Per Share (EPS) has marginally decreased due to the conversion of warrants into equity shares, resulting in an increase in the paid-up share capital. The company has successfully overcome previous quarter challenges and is gearing up for a strong performance in the coming period. Sanjivani currently exports approximately 77% of its revenue across 20 countries and has successfully completed regulatory audits for three additional countries, paving the way for entry into new geographies. The company's new IV fluid manufacturing facility in Pune has started commercial dispatches with a robust forward order book covering the next 90 days.

Key Highlights

  • Net profit of 261.67 Lacs for Q3 2025
  • Revenue from operations at 2086.32 Lacs
  • EPS marginally decreased due to warrants conversion
  • Successfully completed regulatory audits for new market access
  • New IV fluid manufacturing facility in Pune started commercial dispatches
SANJIVIN
Pharmaceuticals
SANJIVANI PARANTERAL LTD.

Price Impact